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Abstract
Background: The discovering of interesting patterns in drug-protein interaction data at molecular level can reveal
hidden relationship among drugs and proteins and can therefore be of paramount importance for such application
as drug design. To discover such patterns, we propose here a computational approach to analyze the molecular
data of drugs and proteins that are known to have interactions with each other. Specifically, we propose to use a
data mining technique called Drug-Protein Interaction Analysis (D-PIA) to determine if there are any commonalities
in the fingerprints of the substructures of interacting drug and protein molecules and if so, whether or not any
patterns can be generalized from them.
Method: Given a database of drug-protein interactions, D-PIA performs its tasks in several steps. First, for each drug
in the database, the fingerprints of its molecular substructures are first obtained. Second, for each protein in the
database, the fingerprints of its protein domains are obtained. Third, based on known interactions between drugs
and proteins, an interdependency measure between the fingerprint of each drug substructure and protein domain
is then computed. Fourth, based on the interdependency measure, drug substructures and protein domains that
are significantly interdependent are identified. Fifth, the existence of interaction relationship between a previously
unknown drug-protein pairs is then predicted based on their constituent substructures that are significantly
interdependent.
Results: To evaluate the effectiveness of D-PIA, we have tested it with real drug-protein interaction data. D-PIA has
been tested with real drug-protein interaction data including enzymes, ion channels, and protein-coupled
receptors. Experimental results show that there are indeed patterns that one can discover in the interdependency
relationship between drug substructures and protein domains of interacting drugs and proteins. Based on these
relationships, a testing set of drug-protein data are used to see if D-PIA can correctly predict the existence of
interaction between drug-protein pairs. The results show that the prediction accuracy can be very high. An AUC
score of a ROC plot could reach as high as 75% which shows the effectiveness of this classifier.
Conclusions: D-PIA has the advantage that it is able to perform its tasks effectively based on the fingerprints of
drug and protein molecules without requiring any 3D information about their structures and D-PIA is therefore very
fast to compute. D-PIA has been tested with real drug-protein interaction data and experimental results show that
it can be very useful for predicting previously unknown drug-protein as well as protein-ligand interactions. It can
also be used to tackle problems such as ligand specificity which is related directly and indirectly to drug design
and discovery.
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Background
In many different and extremely complex ways, the che-
mical pathways in our bodies are affected by various dis-
eases. When one is sick, it might be a mistake in one
reaction in a pathway that stops an important protein
from being produced or causes too much of it to be
produced. To correct such mistakes, drug molecules can
be developed to interact with target protein molecules
to activate or inhibit some of its functions thereby caus-
ing a protein to be produced more, or less. To facilitate
drug design and discovery, it would therefore be very
useful if we can predict whether or not a particular drug
candidate may interact with a particular target protein
based on its their structures at the molecular or sub-
molecular levels.
Over the past decade, a lot of effort has been made to
investigate into how drug and protein interact and the
most notable among the work done are those related to
protein-ligand docking [1]. Ligand is a molecule that
binds to another chemical entity to form a large com-
plex and protein-ligand docking is concerned with the
prediction of the position and orientation of a ligand for
binding with a protein receptor. If a ligand candidate
that binds with a certain target can be found, drug
molecules can then be designed to contain this ligand.
However, the finding of such ligand candidate is difficult
as protein-ligand docking requires knowledge about the
3D structures of the proteins and obtaining such knowl-
edge can be very difficult [2].
Instead of investigating into protein-ligand docking,
there has also been some effort to look into the analysis
of molecular substructures [3] and biological activities
[4]. In [3], for example, the concept of “privileged” sub-
structures is introduced as chemical substructures that
are commonly present in many drugs. In other words,
in predicting if a drug may have any interaction with a
protein, one can search for the presence of such privi-
leged substructures in the drug molecules as an indica-
tor of the likelihood of the existence of an interaction
relationship with a protein. While such approach to
finding privileged substructures may sound reasonable,
it is considered controversial as abundance of drug
structures may be a trivial consequence of their abun-
dance in biochemical molecules.
Other than finding privileged substructures, a variety
of statistical methods have recently been proposed to
predict drug-target or more generally, protein-ligand
interactions [5,6]. There have also been some attempts
to mine structural patterns from biological or biochem-
ical data based on molecular fingerprints. The concept
of molecular fingerprints, which is first introduced in
[7], refers to the representation of chemical structures
originally designed to assist in chemical database search.
They become so widely used later on for data analysis
tasks such as similarity search [8], clustering [9], and
classification [10]. Molecular fingerprints have been
used in such tasks to encode a wide range of 2D and
3D structural or conformational features of the mole-
cules. A novel method for representing and analyzing
3D protein-ligand binding interactions, for example, is
proposed in [11]. The key to the proposed method is to
analyse the fingerprints obtained from translating the
3D structural binding information from a protein-ligand
complex into a one-dimensional binary string.
Most of the work mentioned above has been per-
formed independently from the viewpoints of either
ligands or proteins. Not much work has been done to
investigate into how the chemical and biological space
may interact with each other. In [2], the paper reports
on some attempts made to try to connect the two space.
It proposes an approach to extract drug substructures
and protein domains from a drug-protein interactions
dataset by encoding chemical substructures of the drugs
and the proteins domains of the dataset into molecular
fingerprints. The paper explains how sparse canonical
correspondence analysis (SCCA) can be performed on
the data. As pointed out in the paper, the effectiveness
of the proposed approach depends very much on the
correct setting of a number of predefined parameters
and the method may not work well when sparsity of
data is not a relevant characteristic.
To identify ligand candidates efficiently for such appli-
cations as drug design and discovery, we need to be able
to predict if a drug may interact with a protein without
having to obtain full information of the 3D structures of
protein molecules at an early stage. To do so, we pro-
pose to use a data mining algorithm called D-PIA
(Drug-Protein Interaction Analysis). Instead of relying
on the availability of the 3D structural information of a
target protein to predict if it may have any interaction
with a certain drug candidate, D-PIA only makes use of
the 2D molecular fingerprints of the protein in the pre-
diction process.
Proteins are molecules consisting of a long chain of
amino acids with unique structures and substructures. A
protein domain is a part of a protein chain that can
evolve, function, and exist independently of the rest of
the other parts of the chain [12]. D-PIA performs its
tasks by first breaking down drug molecules into sub-
structures and proteins into their protein domains. By
so doing, D-PIA attempts to determine if the drug sub-
structures may interact or bound with the protein
domains and if the strength of such interactions or
bindings may determine if drugs can be designed for
optimal compatibility with the human body and with
other drugs [13].
Luo and Chan BMC Bioinformatics 2012, 13(Suppl 9):S4
http://www.biomedcentral.com/1471-2105/13/S9/S4
Page 2 of 7
Once the drug substructures and protein domains are
identified, D-PIA makes use of a probabilistic measure
to determine if a drug substructure and a protein
domain are interdependent on each other and it does so
in several steps: (i) for each drug in the database, the
fingerprints of its molecular substructures are first
obtained; (ii) for each protein in the database, the fin-
gerprints of its protein domains are obtained; (iii) based
on known interactions between drugs and proteins, an
interdependency measure between the fingerprint of
each drug substructure and protein domain is then
computed; (iv) based on the interdependency measure,
drug substructures and protein domains that are signifi-
cantly interdependent are identified; and (v) the exis-
tence of interaction relationship between a previously
unknown drug-protein pairs is then predicted based on
their constituent substructures that are significantly
interdependent.
D-PIA has been tested with real data involving two
thousand drugs and the proteins that they interact with.
Our experimental results show that it can be very help-
ful for predicting drug-protein and protein-ligand inter-
actions. It can also be used to address problems such as
ligand specificity.
Methods
Suppose that we have a set of M drugs {D1, D2, ... Di, ..
DM} with each characterized by p substructure descrip-
tors respectively. Suppose also that we have a set of N
proteins {P1, P2, ... Pj, ... PN} with q protein domains
descriptors identified in each of them respectively.
Each of the M drugs can therefore be represented as
Di = (subi1, subi2,..., subix,..., subip), where subix is the xth
substructure of the ith drug where iÎ{1, 2,..., M} and xÎ
{1, 2, ..., p} and subix = 1 when the ith substructure
exists in the drug, otherwise subix = 0. Similarly, each
protein can be represented as Pj = (domj1, domj2,...,
domjy,...,domjq ), where domjy is the yth protein domain
of the jth protein, jÎ{1, 2, ..., N}, yÎ{1,2,..., q} and domjy
= 1 when the yth protein domain domjy exists in the
protein, otherwise domjy = 0. The existence of one of
more interaction relationships between the given drugs
and proteins are represented by a matrix I = (a1, a2,...,
aM)T, where ai = (ai1, ai2,...alk,...aiN), lÎ{1, 2, ..., M}, kÎ
{1, 2,..., N}. alk = 1 when there is an interaction between
the lth drug and kth protein.
Discovering interesting association patterns
To determine whether or not the ith substructure of a
drug has a sufficiently strong interdependency relation-
ship with the jth protein domain of proteins, we con-
struct a contingency table (Table 1) of P rows and Q
columns.
Here in this table, occij denotes the number of occur-
rences of the case when subi and domj both takes on
the value 1 in I. Let expij =
occi+occ+j
T
be the expected
number of occij, where occi+ =
∑Q
k=1 occik and
occ+j =
∑P
k=1 occkj and T =
∑
l,k occlk. An interdependency
relationship between them is considered to exist if occij
is significantly different from expij. To decide if this is
the case, the approach taken in [14] is used to calculate
an adjusted residual test statistic:
adij =
zij√(
1 − occi+
T
)(
1 − occ+j
T
) (1)
where
zij =
occij − expij√expij (2)
and
(
1 − occi+
T
) (
1 − occ+j
T
)
is the maximal likelihood
of zij defined in [15].
adij has an approximate normal distribution with a
mean of approximately zero and a variance of approxi-
mately one. Therefore, if its absolute value exceeds 1.96,
it would be considered significant at a = 0.05 by con-
ventional criteria. Based on (1), we can determine if a
drug substructure subi has an interdependency relation-
ship with the protein domain domj, at the 95% confi-
dence level.
It should be noted that the value of adij can be posi-
tive and negative. When adij is positive, subi and domj is
interdepdent on each other and when adij is negative,
they are not.
Determining the weight of evidence for the discovered
patterns
Since the existing of drug substructure in a drug is
important for determining the interaction between pro-
tein domains, it is necessary to ensure that they are uti-
lized in the prediction of an interaction relationship
between a drug and a protein. The interdependency
relationships discovered by (2) determines only the
Table 1 Observed drug substructures and protein
domains occurrence
dom1 dom2 ... domj ... domQ
sub1 occ11 occ12 ... occ1j occ1Q
sub2 occ21 occ22 ... occ2j occ2Q
...
subi occi1 occi2 ... occij occiQ
...
subP occp1 occp2 ... occpj occpQ
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interdependency between drug substructures and pro-
tein domains, but it does not measure how strong the
interdependency is. For this reason, we introduce the
weight of evidence measure for the patterns discovered
above.
Suppose that domj = 1 is found to be interdependent
with subi = 1. Then the weight of evidence provided by
subi = 1 in favor of domj = 1 opposed to domi = 0 can
be defined as [16]:
WoE
(
domj = 1
domj = 0
: subi = 1
)
= I
(
domj = 1 : subi = 1
)− I (domj = 0 : subi = 1)
(3)
where
I
(
domj = 1 : subi = 1
)
= log
Pr(domj = 1|subi = 1)
Pr(domj = 1)
(4)
I
(
domj = 0 : subi = 1
)
= log
Pr(domj = 0|subi = 1)
Pr(domj = 0)
(5)
WoE can be used to be a positive or negative measure-
ment for supporting or refuting the existence of an
interaction relationship between a drug containing subi
and a protein containing domj to have an interaction
relationship. Hence, for a drug to be predicted to inter-
act with a target protein, it should have sufficient sup-
port from its substructures in the sense that they should
have a large enough degree of interdependency with the
protein domains of the target protein.
Evaluation of D-PIA
One way to evaluate the effectiveness of D-PIA is to see
if it can correctly predict drug-protein interactions that
it has no previous knowledge of. Here we propose to
evaluate D-PIA by testing it to see if it can predict
known drug-target interactions correctly.
Given a pair of drug Di and protein Pj, the potential
interaction between them can be estimated by determin-
ing if there is any significant interdependency between
the substructures in Di and the protein domains in Pj.
To do so, let us denote the set of substructures in Di as
DSi = {s1 , s2 , ..., sa} and the set of domains in Pj as PDj
= {d1 , d2 , ..., db}, where a is the total number of sub-
structures in Di, and b is the total number of protein
domains in Pj. For ∀s’ Î DSi ∀ d’ Î PDi, we consider
the interaction between s’ and d’ as significant when (6)
below is satisfied.
|ads′d′ | > 1.96 (6)
For a pair of Di and Pj, there are a × b possible signifi-
cant interdependency relationship of substructures and
protein domains in total. The potential interaction
between Di and Pj can be estimated based on the inter-
acting substructures between them. If there is only 1 sig-
nificant interdependency between the substructures of a
drug and protein out of the total a × b such possible rela-
tionships, we may consider that the potential interaction
between Di and Pj as very weak. On the other hand, if
more than half of the associations are significant, we may
consider that the potential interaction between Di and Pj
as high. Therefore we could assert that there is potential
interaction between Di and Pj as (7).
w
(
Di,Pj
)
=
i,jval(ads′jd′j)
a × b
(7)
where val(x) = 1 if |x| > 1.96, otherwise val(x) = 0.
The interaction between the drug, Di, and the protein,
Pj, will be more significant if the value of w(Di, Pj) is
higher than some user-supplied threshold, denoted as R,
i.e if w(Di, Pj) >R, and if, at the same time, the WoE(Di,
Pj) is also high, then it means that the interaction
between Di and Pj is not only just strong, but the strong
interaction relationship is also supported with strong
evidence.
Results
To evaluate the effectiveness of D-PIA, we used the
dataset from [2] which contains information about 1862
drugs. Each drug in the dataset is represented by a fin-
gerprint with 881 substructures as defined in the Pub-
Chem database [17], i.e., each drug can be encoded as a
binary vector whose elements encode for the presence
or absence of a chemical substructure using 1 and 0,
respectively. An example of the fingerprint of such a
substructure is given in Figure 1.
Other than the drugs, the dataset also contains infor-
mation about 1554 proteins in total. According to the
UniProt [18] and Pfam database [19], each of them con-
tains a total of 876 protein domains and thus, each pro-
tein can be encoded as a binary vector whose elements
encode for the presence or absence of a protein domain
using 1 and 0 respectively. An example of the protein
sequence and its protein domains is given in Figure 2.
Given the drugs and proteins as described above, D-
PIA determines the adjusted residuals for the drug sub-
structures and protein domains based on Equation (2)
above. In Table 2, we list some of the adjusted residuals
that D-PIA computes to determine if there is significant
interdependency relationship between a drug substruc-
ture and a protein domain. As shown in the table, for
example, the drug substructures of SUB840, SUB841,
SUB861 are interdependent with the protein domains of
PF00104 and PF00105.
To evaluate the effectiveness of D-PIA, we therefore
try to determine if there is a strong enough drug-protein
Luo and Chan BMC Bioinformatics 2012, 13(Suppl 9):S4
http://www.biomedcentral.com/1471-2105/13/S9/S4
Page 4 of 7
interaction between the drugs Di and the protein Pj in
our dataset based on the adjusted residuals obtained
between the substructures of the drugs and the protein
domains of the proteins as illustrated in Table 2. We set
R to 10% in our experiments and found D-PIA to be
able to predict the existence of Drug-Protein interaction
at an accuracy of 85.4%. A 5-fold cross-validation
approach is used to evaluate the ability of D-PIA to
determine if a drug interacts with a protein and this
approach is described as follows:
1) We split the drug-protein interactions dataset into
five subsets of equal size and take each subset in
turn as a test set.
2) We perform D-PIA on the remaining 4 sets.
3) Based on the significant interdependency relation-
ships determined between drug substructures and
protein domains, D-PIA attempts to predict the exis-
tence of interactions between drug and protein in
the testing data and the accuracy over the five folds
are computed.
A ROC (receiver operating characteristic) curve [21]
based on the experimental results can be obtained as
shown in Figure 3.
While w(Di, Pj) represents the existence of a signifi-
cant interdependency relationship between a drug sub-
structure subm and a protein domain domn, it does not
tell us how strong the interdependency relationship is.
To find out, we compute, as discussed above, the WoE
(subm, domn) measure for the interaction between subm
and domn. We summarize the result of the interaction
between the drug substructures subm and protein
domain domn and we present some of the results in
Table 3.
Discussion
The ROC in Figure 3 is a chart of true-positive vs false-
positive for the prediction results of the experiments.
The true-positive is concerned with the rate of correctly
predicted drug-protein interactions whereas the false-
positives is concerned with the rate of incorrectly pre-
dicted drug-protein interactions.
Figure 1 Drug Structure and PubChem Molecular Fingerprint.
Figure 2 An example of protein sequence and its protein domains [20].
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We can see from the chart that D-PIA can be very
accurate in predicting drug-protein interactions most of
the ROC curve is much above the reference line (ran-
dom prediction). The AUC (area under the ROC curve)
score (which is 1 for perfect accuracy and 0.5 for ran-
dom prediction) score for D-PIA is 0.7497 which shows
that that it is much better than prediction at random.
These results show that D-PIA can be used to predict
how likely a drug candidate may interact with a particu-
lar protein. Based on the WoE computed as shown in
Table 3, we also know that candidate drugs that have
the substructures SUB695 are significantly interdepen-
dent with the protein domains PF04960, etc., and we
believe that the interdependency relationships and the
WoE measures between them such as shown in Table 3
could be very useful for the drug discovery, pharmacolo-
gical analysis, ligand specificity, etc.
Conclusions
One common approach to drug discovery is to tackle
the protein-ligand docking problem. To effectively do
so, there is a need for information related to the 3D
Table 2 Some examples of adjusted residuals
PF00102 PF00104 PF00105 PF00106 PF00107
SUB840 -1.447 19.180 18.928 -0.997 -1.282
SUB841 -1.441 18.609 18.354 -0.361 -1.276
SUB843 -0.381 -0.793 -0.790 -0.427 -0.338
SUB846 -0.337 -0.702 -0.699 -0.378 -0.299
SUB848 -0.159 -0.331 -0.330 -0.178 -0.141
SUB861 -1.673 20.748 20.551 1.901 -1.481
Figure 3 ROC curve for the experiments.
Table 3 High value of adjust residual and WoE for drug
protein substructures interactions
Drug
sub
ref.
Drug substructures and
description
Protein
dom.
ref
Adjust
residual
Weight
of
evidence
... ... ... ... ...
SUB17 >=8N PF00156 4.303 2.034
PF00206 3.137 2.359
PF00583 3.279 2.447
PF00858 5.047 2.12
... ... ... ... ...
SUB33 >=1 S PF00017 5.553 4.118
PF00018 3.073 3.506
PF00069 2.363 2.193
PF00169 23.046 7.078
... ... ... ... ...
SUB190 >=2 unsaturated non-
aromatic nitrogen-containing
ring size 6
PF00019 8.96 6.376
PF00020 5.22 4.874
PF00071 7.161 4.254
PF00432 9.429 5.545
... ... ... ... ...
SUB235 >=2 saturated or aromatic
carbon-only ring size 8
PF00020 12.08 7.214
PF00091 5.49 4.089
PF00531 6.814 5.599
PF02180 14.706 6.787
... ... ... ... ...
SUB334 C(~C) (~C) (~C) (~C) PF00133 3.605 1.992
PF02145 2.081 2.669
PF02188 2.081 2.669
PF08264 3.301 1.998
... ... ... ... ...
SUB428 C(#C)(-H) PF00039 5.319 4.926
PF00048 1.582 2.094
PF00104 11.315 2.849
PF00105 11.37 2.859
... ... ... ... ...
SUB695 O=C-C-C-C-C-N PF00120 8.354 4.686
PF04960 9.591 4.671
... ... ... ... ...
SUB707 O=C-C-C-C-C(N)-C PF00040 2.742 3.236
PF00091 29.218 5.237
PF00183 4.55 3.619
PF00340 4.708 4.597
PF00341 2.886 3.357
... ... ... ... ...
29.218 7.214
1.582 1.992
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structures to be known. As such information is difficult
and expensive to obtain, D-PIA is proposed here to dis-
cover patterns in known drug-protein interaction to pre-
dict those that are unknown so that the protein-ligand
docking problem can be more easily tackled without
having to rely on any 3D information. D-PIA makes use
of fingerprints of the known drug substructures and
protein domains to infer the existence of interactions
between corresponding drugs and proteins. Experimen-
tal results show that the D-PIA can work effectively and
can infer drug-protein interaction with high accuracy
and can be a promising tool for computer aided drug
discovery.
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